Journal

Role of Platelets in Chronic Kidney Disease

Read time: 1 mins

Published:16th Jun 2021

Author: Jain N, Corken A, Kumar A, Davis C, Ware J, Arthur J.

Source: Journal of the American Society of Nephrology

Availability: Pay for access, or by subscription

Ref.:J Am Soc Nephrol. 2021 Jun 17:ASN.2020121806.

DOI:10.1681/ASN.2020121806

Role of Platelets in Chronic Kidney Disease

Platelet-dependent mechanisms for excessive clotting and bleeding in CKD remain undefined. Moreover, platelets’ contribution to inflammation, and specifically to CKD, are equally elusive. To date, descriptions of changes in the functional properties of circulating platelets during CKD have provided confusing interpretations. Experimental approaches that can advance our understanding of platelet dysfunction in CKD are needed, and studies that provide mechanistic insights into the dynamic relationships between thrombosis, bleeding, and inflammation associated with CKD will be essential to improve clinical management and outcomes for this vulnerable population. This article summarizes existing literature characterizing platelets in CKD and identifies areas that need further investigation.

Read abstract on library site Access full article

Hyperkalaemia

Containing relevant Learning Zones, guidelines, trials and news.

Chronic Kidney Disease

Containing relevant Learning Zones, guidelines, trials and news.

Glomerulonephritis

Containing relevant Learning Zones, guidelines, trials and news.

Featured Learning Zones

patient receiving dialysis, hospital image

Learning Zone Homepage

Chronic Kidney Disease Learning Zone

Chronic Kidney Disease (CKD) is a disease that can often lead to a need for haemodialysis and kidney transplantation. New CKD treatments are emerging which focus on delaying CKD disease progression and the need for transplantation.

You may be interested in...

Guideline

Management of osteoporosis in postmenopausal women: the 2021 position statement of The North American Menopause Society

Objective: To review evidence regarding osteoporosis screening, prevention, diagnosis, and management in the past decade and update the position statement published by The North American Menopause Society (NAMS) in 2010 regarding the management of osteoporosis in postmenopausal women as new therapies and paradigms have become available.

Guideline

The 2022 hormone therapy position statement of The North American Menopause Society

“The 2022 Hormone Therapy Position Statement of The North American Menopause Society” (NAMS) updates “The 2017 Hormone Therapy Position Statement of The North American Menopause Society” and identifies future research needs.

Guideline

The 2023 nonhormone therapy position statement of The North American Menopause Society

Objective: To update the evidence-based Nonhormonal Management of Menopause-Associated Vasomotor Symptoms: 2015 Position Statement of The North American Menopause Society.